Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

FTSE 100 rises, led by Pearson; Mediclinic sinks as earnings sag

Published 17/10/2018, 10:44
Updated 17/10/2018, 10:50
© Reuters. A red London bus passes the Stock Exchange in London

By Helen Reid

LONDON (Reuters) - Britain's top stock index climbed on Wednesday, with Pearson's outlook impressing the market, while mid-cap Mediclinic sank by a fifth after its results missed estimates.

The FTSE 100 (FTSE) was up 0.3 percent by 0835 GMT after weaker-than-expected inflation data took the pound down a notch. The index is dominated by international exporters, who benefit from a weaker currency.

Shares in education publisher Pearson (L:PSON) topped the FTSE with a 3.9 percent rise after it stuck to its target of returning to profit this year.

"The education giant has been shifting away from more traditional classroom materials in favour of digital, and progress there looks more positive," said Nicholas Hyett, equity analyst at Hargreaves Lansdown.

Pearson is a widely shorted stock, and the amount of shares out on loan has risen this year, data from FIS Astec Analytics showed.

A weak update from mid-cap housebuilder Crest Nicholson (L:CRST) sent the shares down 6.2 percent. That weighed on FTSE 100 housebuilders Persimmon (L:PSN), Taylor Wimpey (L:TW), and Berkeley Group (L:BKGH) which lost 1.6 to 3.2 percent.

Crest Nicholson warned its full-year profit would be lower than expected, citing a challenging real estate market, and said its chief financial officer had stepped down.

Hargreaves Lansdown (L:HRGV) shares gained 3.3 percent after Bernstein analysts upgraded it to "market-perform" from "underperform", saying they were now more convinced its valuation is justified.

Shares in software company Micro Focus (L:MCRO) were also among top gainers, up 3.1 percent as tech shares across Europe climbed.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Overall, analysts are downgrading their earnings estimates for the FTSE 100 as well as the mid-cap FTSE 250 index, which was down 0.1 percent on Wednesday.

"Valuations don't look particularly stretched in absolute terms, but the earnings newsflow is still mixed at best," said Ian Williams, strategist at Peel Hunt.

The mid-cap segment, home to more growth stocks, fell in last week's selloff as investors seemed to turn back to value plays. Growth still had its attractions, though.

"You can be too gung ho about saying I'm rotating into value, if the earnings are still quite disappointing," said Williams.

Mid-caps saw big moves after results and broker notes. Mediclinic (L:MDCM) shares sank 20 percent to the bottom of the FTSE 250 after its earnings and margins missed estimates, hit by weaker performance in its Swiss segment.

"Investors will likely be disappointed by Swiss performance while revised margin guidance may imply another leg down in the Swiss story, introducing further uncertainty," wrote UBS analysts.

Inchcape (L:INCH) shares tumbled 10 percent after HSBC slashed its target price on the stock to 650p from 840p.

Dealmaking was also a mover. Shares in ContourGlobal (L:GLO) climbed 3 percent after the power firm said it was in talks to possibly buy Spanish utility Iberdrola's (MC:IBE) 50-megawatt solar power plant in Spain.

Among small-caps, Asos (L:ASOS) shares jumped 12 percent after the online fashion retailer said its potential was "huge". It narrowly beat forecasts with a 28 percent jump in 2017-18 profits, maintaining guidance for its new financial year.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

"Asos' positive statement should reassure investors today, concerned by recent disappointments in the retail sector (muted sales growth and various profit warnings)," said Stifel analysts.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.